HUTCHMED (China) Ltd Files November 2024 6-K Report
Ticker: HMDCF · Form: 6-K · Filed: Nov 29, 2024 · CIK: 1648257
Sentiment: neutral
Topics: reporting, foreign-private-issuer
TL;DR
HUTCHMED filed its monthly 6-K report, no major news.
AI Summary
HUTCHMED (China) Limited filed a Form 6-K on November 29, 2024, reporting its activities for the month of November 2024. The filing is a routine report for foreign private issuers and does not contain specific financial results or significant corporate events beyond its submission status.
Why It Matters
This filing indicates HUTCHMED is fulfilling its reporting obligations as a foreign private issuer, which is standard practice for companies listed on US exchanges.
Risk Assessment
Risk Level: low — This is a routine filing by a foreign private issuer and does not contain new material information or financial disclosures.
Key Players & Entities
- HUTCHMED (China) Limited (company) — Filer of the report
- 001-37710 (other) — Commission File Number
- 20241129 (date) — Filing date and period of report
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information which the issuer makes or is required to make public in its home country.
What period does this Form 6-K cover?
This Form 6-K covers the month of November 2024, with the filing date as of November 29, 2024.
Is HUTCHMED (China) Limited required to file annual reports under Form 20-F or 40-F?
Yes, HUTCHMED (China) Limited indicates it files annual reports under cover of Form 20-F.
What is the principal executive office address for HUTCHMED (China) Limited?
The principal executive offices are located at 48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.
Does this filing contain specific financial results or material updates?
No, this Form 6-K appears to be a routine submission for the month of November 2024 and does not detail specific financial results or material events within the provided text.
Filing Stats: 183 words · 1 min read · ~1 pages · Grade level 13.4 · Accepted 2024-11-29 06:04:11
Filing Documents
- hcm-20241129x6k.htm (6-K) — 20KB
- hcm-20241129xex99d1.htm (EX-99.1) — 17KB
- hcm-20241129xex99d2.htm (EX-99.2) — 11KB
- hcm-20241129xex99d1001.gif (GRAPHIC) — 4KB
- hcm-20241129xex99d2001.gif (GRAPHIC) — 4KB
- 0001648257-24-000090.txt ( ) — 61KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of Novem ber 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant's name into English) 48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F HUTCHMED (CHINA) LIMITED Form 6-K EXHIBIT INDEX Exhibit No. Description Exhibit 99.1 Press release relating to HUTCHMED announces continued inclusion of ORPATHYS (savolitinib) in the National Reimbursement Drug List in China at current terms Exhibit 99.2 Announcement relating to total voting rights 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. HUTCHMED (CHINA) LIMITED By: /s/ Johnny Cheng Name: Johnny Cheng Title: Chief Financial Officer Date: November 29, 2024 3